Skip Navigation

Your Environment. Your Health.

Infliximab in Polymyositis / Dermatomyositis / Inclusion Body Myositis

Principal Investigator:

Ingrid Lundberg, Karolinska Institute


Study Design:

Phase 2 Open trial, Infliximab dose 5 mg/kg


Types & Number of IIM Studied:

Active Polymyositis/Dermatomyositis/Inclusion Body Myositis with reduced muscle function (N = 15)


Entry Criteria:

Refractory to prednisolone and methotrexate


IMACS Core Set Measures Included:

Physician and Patient Global Activity and Damage Assessments, Health Assessment Questionnaire, Manual Muscle Testing, muscle enzymes, Myositis Disease Activity Assessment Tool; Myositis Damage Index, Health-Related Quality of Life by SF-36


Other Measures Included:

Myositis Functional Index, aerobic capacity, biopsies


Primary Outcome:

Improved functional index and decreased inflammation in muscle biopsies


Study Duration:

16 weeks



Schering Plough



Started in 2003. Enrollment completed.



Ingrid Lundberg, M.D., Ph.D.
Rheumatology Unit
Department of Medicine
Karolinska University Hospital
SE- 171 76 Stockholm, Sweden
Tel +46-8-5177-6087
Fax +46-8-5177-3080


Return to Therapeutic Studies listing

Back to Top